CliffBio
small molecule

EMBEDA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

Loss of exclusivityNovember 2029latest FDA-listed patent expiry
CompanyAlpharma →View the full company profile on CliffBio

Drug detail

Brand nameEMBEDA
Active ingredientMORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Strength30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
8623418November 2029use U-1640
7815934December 2027product
7682633June 2027use U-1510
7682634June 2027product
8877247June 2027product
8846104June 2027product
8158156June 2027use U-1510

More from Alpharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EMBEDA patent cliff — loss of exclusivity November 2029 | CliffBio